Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03012321 |
|
Recruitment Status : Unknown
Verified March 2021 by Maha Hussain, Northwestern University.
Recruitment status was: Recruiting
First Posted : January 6, 2017
Last Update Posted : March 3, 2021
|
Sponsor:
Northwestern University
Collaborators:
AstraZeneca
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Maha Hussain, Northwestern University
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Unknown |
|---|---|
| Estimated Primary Completion Date : | December 2021 |
| Estimated Study Completion Date : | January 2022 |